Integra Lifesciences
(NASDAQ: IART)
is closing its ACell plant in Lafayette, Indiana, letting go of almost all of the workers.
Princeton, New Jersey–based Integra informed the Indiana Department of Workforce Development in a Feb. 13 WARN notice that the closure will result in a layoff of 60 workers — 52 on April 26 and eight on May 31. The number is less than 2% of the 3,722 employees that the company listed in its most recent annual report.
The Lafayette Journal & Courier and other local media broke the news last week. Integra said that it is moving Urinary Bladder Matrix manufacturing to its Columbia, Maryland location. UBM is an extracellular matrix scaffold derived from porcine urinary bladder. Integra Lifesciences uses it in its Cytal wound and Cytal burn matrix, Micromatrix UBM particulate, and Gentrix surgical matrix products.
The company acquired the Urinary Bladder Matrix tech through its more than $300 million acquisition of Columbia, Maryland–based ACell in 2021.
In a statement shared today with MassDevice, Integra said that it is providing support and transition services to affected workers. “As part of our integrated growth strategy, we continually evaluate ways we can strengthen our operational efficiency to better serve our customers, innovate new treatment pathways and maximize the impact we have on restoring patients’ lives.”
A tissue-related products recall — and related temporary facility closure in Boston — weighed on Integra Lifesciences’ results for much of 2023. At its presentation at the annual J.P. Morgan Healthcare Conference in January, the company said that the Boston factory restarted in November, with distribution of its products expected to resume in mid-to-late Q2 2024.
In December, Integra Lifesciences announced that a more than $275 million agreement to acquire Acclarent from Johnson & Johnson MedTech.
Integra Lifesciences reports its Q4 and full-year 2023 financial results on Feb. 28.
